Lack of efficacy of tocilizumab in mucocutaneous Behçet's syndrome: Report of two cases

Rheumatology (United Kingdom)

Volumn 52, Issue 10, 2013, Pages 1923-1924

  Diamantopoulos, Andreas P ^a,b   Hatemi, Gulen ^c  

^a Department of Rheumatology Hospital of Southern Norway Trust   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB;

ADULT; BEHCET DISEASE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLICULITIS; GENITAL ULCER; HUMAN; LETTER; MOUTH ULCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSTERNAL PAIN; TREATMENT RESPONSE; VASCULITIS;

EID: 84887379800     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket130     Document Type: Letter

References (11)

1. Suzuki Kurokawa M, Suzuki N. Behcet's disease. Clin Exp Med 2004;4:10-20.
2. Hatemi G, Silman A, Bang D et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 2009;68:1528-34.
3. Unizony S, Arias-Urdaneta L, Miloslavsky E et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012;64:1720-9.
4. Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for neuro-Behcet's disease, the first report. Clin Neurol Neurosurg 2012;114:297-8.
5. Hirano T, Ohguro N, Hohki S et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012;22:298-302.
6. Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012;30(Suppl 72):S73-5.
7. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990;335:1078-80.
8. Gul A, Tugal-Tutkun I, Dinarello CA et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis 2012;71:563-6.
9. Amadi-Obi A, Yu CR, Liu X et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007;13:711-8.
10. Borhani Haghighi A, Ittehadi H, Nikseresht AR et al. CSF levels of cytokines in neuro-Behcet's disease. Clin Neurol Neurosurg 2009;111:507-10.
11. Hatemi G, Yazici H. Behcet's syndrome and microorganisms. Best Pract Res Clin Rheumatol 2011;25:389-406.